4/29/2010 2:56:20 PM
ACTON, MASSACHUSETTS, April 28, 2010 – Howard L. Levine, Ph.D., President, Susan Dana Jones, Ph.D., Vice President and Senior Consultant, and Patricia Seymour, Senior Consultant, of BioProcess Technology Consultants will be featured speakers at the 2010 BIO International Convention, May 3-6, in Chicago, Illinois.
Dr. Levine will chair the panel discussion, “Disruptive Technologies for the Future of Biomanufacturing,” in the Exciting Science Session of the main conference at 8:00 AM on Tuesday, May 4. The panel will address recent developments in biomanufacturing technology that may transform the global biologics and vaccines industries, including revolutionary technologies that could disrupt the current cell culture-based manufacturing paradigm. Dr. Levine will also be interviewed by Laura Bush, Editor of BioPharm International, on Wednesday, May 5, on “The State of the Art of Process Development and Manufacturing Technologies for Monoclonal Antibodies” at the BioPharm Vidcasting & Networking Theatre Booth in the BIO Exhibition Hall. He will cover highlights of BioProcess Technology Consultants’ recent report, The Development of Therapeutic Monoclonal Antibody Products.
Dr. Jones will be interviewed on Wednesday, May 5, by Jim Miller, President of PharmSource, about “How Outsourcing Can Accelerate Early CMC Development” at the BioPharm Vidcasting & Networking Theatre Booth in the BIO Exhibition Hall. She will draw upon her experience and case studies to address the benefits of using third party organizations to perform some or all aspects of development.
Ms. Seymour will discuss “The Challenges of Demonstrating Comparability of Biosimilar Products,” at 11:30 AM on Wednesday, May 5, at the BioProcess International BioProcess Zone, Booth #5038 in the BIO Exhibition Hall. She will discuss the CMC issues of cell line development, process development, analytical methods development, and manufacturing critical in developing a biosimilar product and demonstrating its comparability with the innovator reference.
“The BIO International Convention is the foremost global gathering of the industry’s innovators, business leaders, and decision makers, and we are pleased attendees will be able to benefit from our insight and experience in the development and manufacturing of biologic products,” said Dr. Levine. For more details, see the BIO conference website at http://convention.bio.org.
In addition to these presentations and interviews, several BioProcess Technology Consultants reports will be available for sale in the BIO Store throughout the conference. The Development of Therapeutic Monoclonal Antibody Products (February 2010) is a comprehensive review and analysis of the Chemistry, Manufacturing, and Control (CMC) activities for the development of monoclonal antibody products, from discovery through First-In-Human clinical trials. Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice guides analyze the latest GxP regulations and guidances in the US, Canada, the European Union, and Japan.
About BioProcess Technology Consultants, Inc.
Founded in 1994, BioProcess Technology Consultants is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company specializes in helping develop manufacturing processes and strategies and assists in developing product discovery and process development programs to speed products from clone to commercial.® BioProcess Technology Consultants also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more about BioProcess Technology Consultants, visit http://www.bioprocessconsultants.com.